- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02529449
Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus
14 de março de 2019 atualizado por: Astellas Pharma Inc
A Phase 2, Clinical Pharmacological Study of ASP1941 in Japanese Patients With Type 1 Diabetes Mellitus
The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2 weeks.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
43
Estágio
- Fase 2
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Aichi, Japão
- Site JP00006
-
Fukuoka, Japão
- Site JP00002
-
Gunma, Japão
- Site JP00009
-
Ibaraki, Japão
- Site JP00001
-
Kanagawa, Japão
- Site JP00008
-
Kanagawa, Japão
- Site JP00005
-
Okayama, Japão
- Site JP00003
-
Osaka, Japão
- Site JP00004
-
Osaka, Japão
- Site JP00010
-
Osaka, Japão
- Site JP00011
-
Tokyo, Japão
- Site JP00007
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
20 anos a 74 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
At the time of obtaining informed consent:
- Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin therapy for at least 52 weeks (364 days).
- Subject is able to be admitted to the site as scheduled.
- Subject is able to record in Patient's diary from the first study drug dose in observation period until the day before the end of post observation.
At screening period:
- Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured only once within the allowance range in screening period. Re-measured HbA1c (NGSP) value will be adopted for the determination.
- Subject has been receiving insulin therapy at daily doses (instructed by a doctor) within a ±20% range for at least 12weeks (83days) prior to the start of screening.
- Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.
- Subject receives treatments for complications (except for transient diseases such as a cold) that, in the investigator's or sub-investigator's opinion, need not to be changed during the period from the start of screening to the end of the treatment period.
- Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.
Exclusion Criteria:
At the time of obtaining informed consent:
- Subject has type 2 diabetes mellitus.
- Subject has participated or has been participating in a clinical study or a post marketing study of another drug or medical equipment within 12 weeks (84 days) prior to obtaining informed consent.
- Subject has received ASP1941 (ipragliflozin) with the exception of placebo.
At screening period:
- Subject has proliferative retinopathy (subjects with stable condition after photocoagulation etc. may be enrolled in the study).
- Subject has developed hypoglycemia unawareness (requires help of a third person) or severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days) prior to the start of screening.
- Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the start of screening.
- Subject has chronic disease(s) which require the continuous use of corticosteroids or immunosuppressants (oral administration, injection, inhalation, or suppository).
- Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83 days) prior to the start of screening.
- Subject with perioperative, severe infection or serious injury.
- Subject whose serum creatinine value exceeds the upper limit of normal range at screening.
- Subject has a urinary albumin/urinary creatinine ratio>300 mg/g in urinalysis at screening.
- Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, and/or renal transplant.
- Subject has AST and ALT >2 ×ULN or T-Bil >1.5 × ULN at screening, or has a history of serious hepatic diseases.
- Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.
- Subject has a history of recurrent urinary tract infections and recurrent genital infections (developed 3 times or more within 24 weeks (168 days) prior to the start of screening).
- Subject has urinary tract infection or genital infection with subjective symptoms.
- Subject has a history of angina unstable, myocardial infarction, angioplasty, and serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start of screening, or has complications of heart disease that, in the investigator's or sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.
- Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).
- Subject has serious gastrointestinal disease or a history of serious gastrointestinal operation.
- Subject has malignant tumors concomitantly (subject may be enrolled in the study if the subject has a history of a malignant tumor which has not recurred without any treatment within 5 years prior to the start of screening).
- Subject has psychiatric disorder that makes the subject unsuitable for study participation.
- Subject has drug addiction or alcohol abuse.
- Subject has a history of drug allergies.
- Subject is unable to adhere to any of the compliance such as hospital visits and dose instruction specified in this study, or does not agree with it.
- Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days prior to the start of screening.
- Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
uma vez por dia
|
Oral
|
|
Experimental: ASP1941 Low dose group
once daily
|
Oral
Outros nomes:
|
|
Experimental: ASP1941 Middle dose group
once daily
|
Oral
Outros nomes:
|
|
Experimental: ASP1941 High dose group
once daily
|
Oral
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Daily profile of plasma glucose levels
Prazo: up to Day 14
|
up to Day 14
|
|
|
Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels
Prazo: at Day -1, Day 1 and Day 14
|
at Day -1, Day 1 and Day 14
|
|
|
AUC0-3h of plasma glucose levels
Prazo: at Day -1, Day 1 and Day 14
|
at Day -1, Day 1 and Day 14
|
|
|
AUC0-4h of plasma glucose levels
Prazo: up to Day 14
|
up to Day 14
|
|
|
AUC0-10h of plasma glucose levels
Prazo: up to Day 14
|
up to Day 14
|
|
|
Fasting plasma glucose levels
Prazo: up to Day 21
|
up to Day 21
|
|
|
Glycoalbumin
Prazo: up to Day 21
|
up to Day 21
|
|
|
Urinary glucose excretion
Prazo: up to Day 14
|
up to Day 14
|
|
|
Urinary glucose excretion rate
Prazo: up to Day 14
|
up to Day 14
|
|
|
Urine volume
Prazo: up to Day 14
|
up to Day 14
|
|
|
Urinary glucose concentration
Prazo: up to Day 15
|
up to Day 15
|
|
|
Body weight
Prazo: up to Day 21
|
up to Day 21
|
|
|
Renal glucose clearance
Prazo: up to Day 14
|
up to Day 14
|
|
|
Plasma concentration of unchanged ASP1941
Prazo: up to Day 14
|
up to Day 14
|
|
|
Urinary concentration of unchanged ASP1941
Prazo: up to Day 14
|
up to Day 14
|
|
|
Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)
Prazo: at Day 1
|
at Day 1
|
|
|
PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)
Prazo: at Day 1 and Day 14
|
at Day 1 and Day 14
|
|
|
Safety assessed by vital signs
Prazo: up to Day 21
|
Supine blood pressure and supine pulse rate
|
up to Day 21
|
|
Safety assessed by 12-lead electrocardiogram
Prazo: up to Day 21
|
up to Day 21
|
|
|
Safety assessed by laboratory tests
Prazo: up to Day 21
|
Hematology, biochemistry and urinalysis
|
up to Day 21
|
|
Safety assessed by self-monitored blood glucose levels
Prazo: up to Day 21
|
up to Day 21
|
|
|
Safety assessed by Adverse events
Prazo: up to Day 21
|
up to Day 21
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de setembro de 2015
Conclusão Primária (Real)
19 de março de 2016
Conclusão do estudo (Real)
19 de março de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
18 de agosto de 2015
Enviado pela primeira vez que atendeu aos critérios de CQ
19 de agosto de 2015
Primeira postagem (Estimativa)
20 de agosto de 2015
Atualizações de registro de estudo
Última Atualização Postada (Real)
18 de março de 2019
Última atualização enviada que atendeu aos critérios de controle de qualidade
14 de março de 2019
Última verificação
1 de março de 2019
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios do Metabolismo da Glicose
- Doenças Metabólicas
- Doenças do sistema imunológico
- Doenças autoimunes
- Doenças do Sistema Endócrino
- Diabetes Mellitus
- Diabetes Mellitus, Tipo 1
- Hipoglicemiantes
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores do transportador de sódio-glicose 2
- Ipragliflozina
Outros números de identificação do estudo
- 1941-CL-6001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Não
Descrição do plano IPD
Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .